TABLE 1.
Patient profiles
| Patient | No. of CD4 cells/mm3 | No. of HIV RNA copies/ml | Duration (mo) of antiviral therapy | Anti-HIV-1 agents receiveda |
|---|---|---|---|---|
| B | 361 | 247,000 | 64 | AZT, ddI, ddC, d4T, 3TC, ABC, IDV, RTV, SQV, APV, DLV |
| C | 3 | 554,000 | 46 | AZT, ddI, ddC, d4T, 3TC, ABC, IDV, RTV, SQV, APV |
| G | 568 | 60,000 | 81 | AZT, ddI, ddC, d4T, 3TC, ABC, IDV, SQV, APV, DLV |
| EV | 185 | 68,000 | 24 | AZT, 3TC, ABC, RTV, SQV, APV, EFV |
| ES | 8 | 42,000 | 34 | AZT, ddI, ddC, d4T, 3TC, ABC, IDV, RTV, APV, EFV, HU |
| EY | 140 | 10,000 | 36 | AZT, ddI, d4T, 3TC, ABC, IDV, RTV, APV, EFV, HU |
a
ddC, zalcitabine; EFV, efavirenz; HU, hydroxyurea. Levels of HIV RNA in serum were determined by using a branched DNA assay.